Posts

Moonwalk raises $70 million to develop fat-targeted siRNA obesity therapy

on
Moonwalk Biosciences has raised $70 million in an oversubscribed Series B round to advance MW101, its lead small-interfering RNA (siRNA) obesity treatment. The financing was co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures, and Future Ventures. MW101 is designed to deliver siRNA directly to adipose tissue and modulate fat-cell biology rather than suppress appetite through GLP-1 or other incretin pathways. In preclinical studies, Moonwalk says MW101 reduced body weight and fat mass while preserving lean mass and without reducing food intake. These findings have not yet been demonstrated in humans. The new funding will support IND-enabling work and first-in-human studies planned for late 2027, as well as additional programs targeting obesity and cardiometabolic diseases. Moonwalk’s proposed advantages include less frequent dosing, potentially improved tolerability, and reduced muscle loss—but th...

Pharvaris stock jumps after pivotal Phase 3 success in hereditary angioedema

on

Amgen’s Imdelltra lands major new lung cancer victory

on

Inhibitor Therapeutics reports clinical, regulatory, formulation and legal progress

on

Brainomix AI analysis adds support for Endeavor’s IPF therapy

on

BII allocates €8 million in follow-on funding to six startups

on

Wegovy helped 40.4% of children in phase 3 obesity trial reach a non-obese BMI

on

Novartis’s Pelacarsen Fails to Reduce Cardiovascular Risk in Phase 3 Trial

on

Novartis stock drops after Avidity centerpiece fails Phase 3 trial

on

Sandoz targets 100+ biosimilars by 2040 with new $300 million Slovenia facility

on

Inhibrx’s OX40 data provide a rationale—not yet proof—for a cancer-vaccine combination

on

FDA approves AstraZeneca’s oral SERD camizestrant despite negative advisory-panel vote

on

BrainChild Bio raises $116M to advance CAR-T therapy for pediatric brain cancer

on